Processing...
Clinical Trials for Breast Cancer
Search
Search
There are 321 active trials for advanced/metastatic breast cancer.
Click on a trial to see more information.
321 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Eligible patients are adults with metastatic or advanced solid tumors—including breast, non-small cell lung (EGFR-mutant or wild-type), gastric, gastroesophageal, or colorectal cancer—who have progressed on, are intolerant to, or lack access to standard therapies. The investigational treatment is DM001, a bispecific antibody-drug conjugate targeting TROP2 and EGFR and delivering a topoisomerase I inhibitor, administered intravenously every 21 days.
ClinicalTrials.gov ID: NCT06475937
TrialFetch AI summary: This trial enrolls adults with metastatic, measurable solid tumors (including GI, GU, breast, ovarian, endocrine tumors, NSCLC, and multiple myeloma with plasmacytomas) who have progressed after standard therapies, and treats them with autologous T-cells genetically engineered to express T-cell receptors targeting patient-specific tumor neoantigens, following lymphodepletion, with or without the addition of pembrolizumab. The investigational TCR therapy directly targets mutated or viral antigens unique to each patient’s cancer in an effort to induce durable tumor regression.
ClinicalTrials.gov ID: NCT03412877
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic ER+ HER2- breast cancer, mCRPC, or NSCLC who have progressed after standard therapies, to receive OP-3136, an oral selective KAT6A/B inhibitor targeting key epigenetic regulators, as monotherapy. Eligible patients must have unresectable disease or no further effective standard treatment options.
ClinicalTrials.gov ID: NCT06784193
TrialFetch AI summary: This trial enrolls adults with unresectable, locally advanced or metastatic solid tumors—including a wide range such as head and neck, lung, bladder, prostate, breast, colorectal, and others—who have progressed on or are intolerant to standard therapies. Patients receive MGC026, a B7-H3-targeted antibody-drug conjugate delivering a topoisomerase I inhibitor (exatecan), with cohorts in both dose escalation and expansion phases.
ClinicalTrials.gov ID: NCT06242470
TrialFetch AI summary: Eligible adult patients with advanced or metastatic solid tumors (including dedicated cohorts for TNBC and melanoma) whose disease is refractory or progressed after standard therapy may receive intratumoral STX-001, a self-replicating mRNA encoding IL-12, as monotherapy or combined with pembrolizumab. Enrollment requires an accessible lesion for injection/biopsy and ECOG 0-1.
ClinicalTrials.gov ID: NCT06249048
TrialFetch AI summary: Eligible patients are adults with advanced, folate receptor alpha–expressing solid tumors—including ovarian, endometrial, cervical, non-small cell lung, triple-negative breast, pancreatic, or colorectal cancer—without uncontrolled CNS metastases or significant comorbidities. Treatment involves investigational LY4170156, a topoisomerase I inhibitor antibody-drug conjugate targeting FRα, given as monotherapy or combined with bevacizumab or carboplatin.
ClinicalTrials.gov ID: NCT06400472
TrialFetch AI summary: Eligible patients are adults with advanced or metastatic solid tumors—especially those with CCNE1-amplified ovarian, endometrial, gastric/GEJ, or esophageal adenocarcinoma, small cell lung cancer, triple-negative breast cancer, or HR+ HER2- breast cancer post-CDK4/6 inhibitor—who have exhausted standard therapies, receiving oral NKT3964, a selective CDK2 PROTAC degrader targeting the CDK2/cyclin E pathway.
ClinicalTrials.gov ID: NCT06586957
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors who have progressed after standard therapies to receive DB-1310, a HER3-targeting antibody-drug conjugate with a topoisomerase I inhibitor payload, as monotherapy or in combination with trastuzumab (HER2+ breast cancer) or osimertinib (EGFR-mutant NSCLC). Key eligibility includes measurable disease, ECOG 0-1, and no prior HER3-ADC or topoisomerase I inhibitor exposure.
ClinicalTrials.gov ID: NCT05785741
TrialFetch AI summary: Eligible patients are adults with metastatic solid tumors (ECOG 0-1, measurable disease, adequate organ function) who will receive MDX2001, a tetraspecific antibody that engages T cells via CD3/CD28 and targets TROP2 and c-MET on tumor cells. The trial excludes individuals with major cardiac disease, active brain metastases, uncontrolled infections, or unresolved toxicities.
ClinicalTrials.gov ID: NCT06239194
TrialFetch AI summary: Adults with unresectable, advanced, or metastatic solid tumors (including NSCLC, colorectal, HNSCC, pancreatic, ovarian, or breast cancer) that are both HLA-A*02:01 positive and harbor the TP53 R175H mutation, and who have progressed on prior therapy, may receive NT-175, an autologous T cell product genetically engineered with a TCR targeting TP53 R175H and rendered resistant to TGF-β mediated immunosuppression. Treatment includes leukapheresis, lymphodepletion (fludarabine/cyclophosphamide), NT-175 infusion, and short-course subcutaneous IL-2.
ClinicalTrials.gov ID: NCT05877599